Cartesian Therapeutics Inc. (RNAC)
NASDAQ · Healthcare
Cartesian Therapeutics Inc. Operating Income 2014–2025
Cartesian Therapeutics Inc. annual/quarterly operating income history and growth rate from 2014 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Cartesian Therapeutics Inc. operating income for the quarter ending March 31, 2026 was -26.5 M, a 21.06% increase year-over-year.
- Cartesian Therapeutics Inc. operating income for the twelve months ending March 31, 2026 was -91.3 M, a 201.89% increase year-over-year.
- Cartesian Therapeutics Inc. annual operating income for 2025 was -143.4 M, a 226.69% increase from 2024.
- Cartesian Therapeutics Inc. annual operating income for 2024 was -43.9 M, a 49.20% decrease from 2023.
- Cartesian Therapeutics Inc. annual operating income for 2023 was -86.4 M, a 694.41% decrease from 2022.
- Cartesian Therapeutics Inc. annual operating income for 2022 was 14.5 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Cartesian Therapeutics Inc. Operating Income — FAQ
Cartesian Therapeutics Inc. (RNAC) operating income over the last 12 years — annual and quarterly figures with year-over-year growth and charts.
What is Cartesian Therapeutics Inc.'s operating income?
Cartesian Therapeutics Inc. (RNAC) reported operating income of -$143M for fiscal 2025.
Where can I see RNAC's operating income history?
The chart and table above show Cartesian Therapeutics Inc.'s operating income by year and by quarter, including the growth rate.